Eupraxia Pharmaceuticals【EPRX】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

3.20

買値

3.02

売値

4.80

出来高

583

3.09 日の範囲 3.20

2.20 52 週間の範囲 4.08

時価総額

113.992M

前日終値

3.01

始値

3.09

時刻

3.01

最終取引時間

財務取引量

US$ 1,866

VWAP

3.20

平均取引量 (3 か月)

17,312

発行済株式数

35,622,553

配当利回り

PER

-5.84

1 株当たり利益 (EPS)

-0.79

歳入

純利益

-28.22M

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient be... Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.eupraxiapharma.com

本社

Victoria, British Columbia, Can

設立

Eupraxia Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker EPRX. The last closing price for Eupraxia Pharmaceuticals was US$3.01. Over the last year, Eupraxia Pharmaceuticals shares have traded in a share price range of US$ 2.20 to US$ 4.08.

Eupraxia Pharmaceuticals currently has 35,622,553 shares in issue. The market capitalisation of Eupraxia Pharmaceuticals is US$107.22 million. Eupraxia Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.84.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.2	6.66666666667	3	3.2	2.84	9018	3.06774367	CS
4	0.1258	4.09212152755	3.0742	3.23	2.75	6331	3.08675398	CS
12	0.73	29.5546558704	2.47	4.08	2.326	17312	3.27878547	CS
26	0.52	19.4029850746	2.68	4.08	2.2	11766	3.04188972	CS
52	-0.35	-9.85915492958	3.55	4.08	2.2	15303	2.93897157	CS
156	-0.35	-9.85915492958	3.55	4.08	2.2	15303	2.93897157	CS
260	-0.35	-9.85915492958	3.55	4.08	2.2	15303	2.93897157	CS

EPRX - Frequently Asked Questions (FAQ)

What is the current Eupraxia Pharmaceuticals share price?

The current share price of Eupraxia Pharmaceuticals is US$ 3.20

How many Eupraxia Pharmaceuticals shares are in issue?

Eupraxia Pharmaceuticals has 35,622,553 shares in issue

What is the market cap of Eupraxia Pharmaceuticals?

The market capitalisation of Eupraxia Pharmaceuticals is USD 107.22M

What is the 1 year trading range for Eupraxia Pharmaceuticals share price?

Eupraxia Pharmaceuticals has traded in the range of US$ 2.20 to US$ 4.08 during the past year

What is the PE ratio of Eupraxia Pharmaceuticals?

The price to earnings ratio of Eupraxia Pharmaceuticals is -5.84

What is the reporting currency for Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals reports financial results in USD

What is the latest annual profit for Eupraxia Pharmaceuticals?

The latest annual profit of Eupraxia Pharmaceuticals is USD -28.22M

What is the registered address of Eupraxia Pharmaceuticals?

The registered address for Eupraxia Pharmaceuticals is 201 - 2067 CADBORO BAY ROAD, VICTORIA, BRITISH COLUMBIA, V8R 5G4.

What is the Eupraxia Pharmaceuticals website address?

The website address for Eupraxia Pharmaceuticals is www.eupraxiapharma.com

Which industry sector does Eupraxia Pharmaceuticals operate in?

Eupraxia Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M